Skip to main content
Getinge logo

Getinge — Investor Relations & Filings

Ticker · GETI ISIN · SE0000202624 LEI · 5493003PZ4F570G3W735 ST Manufacturing
Open in API
Filings indexed 648 across all filing types
Latest filing 2023-02-01 Interim / Quarterly Rep…
Country SE Sweden
Listing ST GETI

About Getinge

https://www.getinge.com/int/

Getinge is a global medical technology company that provides products and solutions for hospitals and life science institutions. The company's offerings are designed to improve clinical outcomes and support healthcare professionals. Its portfolio is focused on three main areas: Acute Care Therapies, Life Science, and Surgical Workflows. Key products include equipment and systems for intensive care, cardiovascular procedures, operating rooms, and sterile reprocessing. Notable solutions feature advanced ventilators like the Servo-u, extracorporeal life support systems such as Cardiohelp II, and equipment for biopharmaceutical production. The company also offers training and educational services to enhance clinical expertise.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport' (Interim Report) and covers the period 'Januari – December 2022'. It contains comprehensive financial statements, including income statements, balance sheet summaries, and detailed breakdowns of revenue and order intake by region and business area. It is clearly a full interim/quarterly financial report rather than a brief announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). FY 2022
2023-02-01 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report' and covers the period 'January – December 2022'. It contains detailed financial statements, including order intake, net sales, and earnings trends, as well as management commentary. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. FY 2022
2023-02-01 English
U.S. Food and Drug Administration broadens the consent decree with Getinge and includes its subsidiary Datascope
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled "Press release" and discusses a significant regulatory event: the broadening of a Consent Decree with the U.S. Food and Drug Administration (FDA) involving a subsidiary. It details compliance issues, planned improvements, and includes contact information for media and investor relations, concluding with a statement about obligations under the EU Market Abuse Regulation. This format is characteristic of a general regulatory announcement or press release concerning a material event, rather than a formal financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A or AGM-R). Since it is a material regulatory announcement that doesn't fit the specific categories like DIRS, DIV, or CAP, the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements.
2022-11-21 English
Amerikanska FDA utökar Getinges förlikningsavtal till att omfatta dotterbolaget Datascope
Legal Proceedings Report Classification · 99% confidence The document is titled "Pressmeddelande" (Press Release) and dated November 21, 2022. It announces a significant legal/regulatory event: the US FDA expanding an existing consent decree to include the subsidiary Datascope due to compliance issues related to quality management systems. It also mentions a scheduled conference call and provides links to download a presentation. Since this is a specific announcement regarding a regulatory action (FDA consent decree/warning letter) that impacts operations and compliance, it falls under the category of a significant legal/regulatory update. While it mentions a presentation, the core content is the legal/regulatory development. This type of material, especially when issued as a press release detailing legal proceedings or regulatory actions, best fits the Legal Proceedings Report (LTR) category, as it details the outcome and implications of regulatory scrutiny (FDA warnings/inspections). It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), but a specific update on a legal/regulatory matter.
2022-11-21 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January to September 2022. It contains comprehensive financial statements, including income statements, balance sheet data, and detailed management analysis of business performance, regional results, and segment-specific metrics. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-10-19 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report' and covers the period 'January – September 2022'. It contains detailed financial statements, including order intake, net sales, and earnings performance, as well as management commentary on business trends. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-10-19 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.